Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New EU-Funded Consortium Aims To Develop Targeted Cancer Vaccines

This article was originally published in The Pink Sheet Daily

Executive Summary

A clinical trial is expected to start in the U.S. and Europe in 2014 of an individualized approach to developing a cancer vaccine for glioblastoma patients.

You may also be interested in...



European Notebook: Renewed Calls For German Pricing Law Changes, Spain Gauges The Value Of Innovation

German health insurers run a cash surplus in the first quarter; Celesio CEO dismissed; Bayer celebrates 150 years; Spain wants to evaluate value for drug pricing; France's drug spend declines in 2012, and more.

Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy

Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.

ScanCell’s DNA Plasmid-Cancer Vaccine Shows Promise In Melanoma

ScanCell Holdings’ potential DNA cancer vaccine, which is administered via an electrical field-driven device, shows preliminary evidence of efficacy in late-stage melanoma patients.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS076064

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel